RSV in Older Adults: Europe's Urgent Call for Policy Action

Respiratory Syncytial Virus (RSV), long recognized as a primary cause of pediatric respiratory illness, is increasingly identified as a substantial and often underestimated public health threat to older adults, causing severe disease, hospitalizations, and mortality. The article, or closely related publications in prominent medical journals, underscores the urgent need for comprehensive policy action, particularly across Europe, to address this significant burden. The European Medical Journal (EMJ), a peer-reviewed, open-access publication, serves as a credible platform for disseminating such critical medical insights. EMJ is known for combining leading editorials from key opinion leaders with news coverage from major congresses, aiming to advance learning and knowledge in the medical sciences. It adheres to rigorous ethical standards and employs a double-blind peer-review process, ensuring the quality and reliability of its content. Key claims highlighted in the analysis of relevant articles reveal that adult immunization policies for RSV across Europe are notably fragmented and underdeveloped, despite the availability of new RSV vaccines. There are significant gaps in RSV surveillance systems, which predominantly focus on children, leaving the burden on older adults largely underrepresented and poorly monitored. This leads to limited or absent age-specific monitoring and insufficient training and communication initiatives for healthcare providers (HCPs) and the general public regarding the risks and preventive measures for adult RSV. The epidemiological data presented in corroborating studies paint a stark picture. In Europe alone, RSV is responsible for over 158,000 hospitalizations annually among adults, with a staggering 92% occurring in individuals aged 65 and older. Globally, a 2019 meta-analysis estimated approximately 5.2 million confirmed RSV-Acute Respiratory Illness (ARI) cases in adults aged 60 years or older in high-income countries, leading to 470,000 hospitalizations and 33,000 in-hospital deaths. These figures underscore that the disease burden of RSV in older adults is substantial and comparable to, or even exceeding, that of influenza. Prevalence rates of RSV in older adults across Europe have been reported to range from 1% to 64.7% in various studies, often compounded by a high prevalence of comorbidities that exacerbate disease severity. Hospitalization rates vary between 12.6% and 55.9%, while mortality rates range from 2.15% to 13%, reaching as high as 36% in intensive care settings. For instance, a Spanish study found RSV caused 84.7 hospitalizations per 100,000 among people older than 60 years, with rates increasing significantly with age and among those with underlying health conditions or living in nursing homes. The call for policy action is multifaceted. Experts recommend strengthening surveillance infrastructure to gather more accurate, age-specific data on RSV incidence and severity in older populations. This improved surveillance is crucial for informing public health decisions and allocating resources effectively. Ensuring equitable access to newly available RSV vaccines is another critical priority. Despite the recent approval of RSV vaccines for adults aged 60 and above by regulatory bodies like the FDA and recommendations from advisory committees in countries like the US, widespread and consistent implementation of immunization programs is still lacking in many European countries. Furthermore, enhancing professional training for healthcare providers and public awareness campaigns are vital to improve diagnosis, prevention, and vaccination uptake among older adults. Many HCPs and the public remain largely unaware of the serious implications of RSV beyond childhood. The current environment, heightened by experiences with the COVID-19 pandemic, offers a unique opportunity to educate and inform about the dangers of respiratory viruses like RSV. While the specific policy recommendations and surveillance data discussed in these articles are primarily centered on European countries, the underlying public health issue is global. India, with its rapidly growing elderly population, faces similar, if not more pronounced, challenges regarding infectious disease burden, healthcare infrastructure, public awareness, and vaccine accessibility. Therefore, the findings and calls for action resonate strongly with the public health needs and priorities in India, emphasizing the critical importance of a proactive approach to RSV in older adults. Policy frameworks implemented in Europe could serve as valuable models for India and other nations grappling with similar demographic shifts and healthcare demands. The urgency is amplified by the potential for RSV to severely impact an already burdened healthcare system, highlighting the need for robust, prevention-oriented healthcare strategies. In summary, the substantial and often underrecognized burden of RSV in older adults demands immediate and coordinated policy interventions. These include strengthening surveillance, ensuring equitable vaccine access, and enhancing public and professional awareness to protect vulnerable populations and build more resilient, prevention-focused healthcare systems globally.

Frequently Asked Questions

Read Full Story on Quick Digest